Understanding Post-Prandial Hyperglycemia in Patients with Type 1 and Type 2 Diabetes: A Web-based Survey in Germany, the UK, and USA by unknown
ORIGINAL RESEARCH
Understanding Post-Prandial Hyperglycemia
in Patients with Type 1 and Type 2 Diabetes:
A Web-based Survey in Germany, the UK, and USA
Meryl Brod . Annie Nikolajsen . James Weatherall . Kathryn M. Pfeiffer
Received: April 4, 2016 / Published online: May 27, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: To explore how patients
with diabetes experience post-prandial
hyperglycemia (PPH) or elevated blood glucose
(BG) following a meal.
Methods: A web-based survey of patients with
type 1 or type 2 diabetes using bolus insulin in
Germany, the USA, and the UK was conducted.
Results: A total of 906 respondents completed
the survey. PPH was a frequent occurrence
among patients with type 1 and type 2
diabetes; 61.9% of respondents had
experienced PPH in the past week, and
differences by diabetes type were not
significant. More than half of the respondents
reported that they knew they were experiencing
PPH because they had measured their BG
(64.8%) and/or because they ‘‘just didn’t feel
right’’ (51.9%). The most frequently reported
reasons given for PPH were eating more
fat/sugar than estimated (31.2%) and
over-eating in terms of their calculated bolus
insulin dose (30.4%). The most common
situations/factors contributing to PPH were
stress (27.4%), eating at a restaurant (24.9%),
being busy (21.1%), and/or feeling tired
(19.2%). The most frequent corrective actions
respondents took following PPH were testing
BG and taking bolus insulin based on the
reading (62.0%), and/or eating less/more
carefully at their next meal or snack (18.8%).
Additionally, significant differences in the
reasons and contributing factors given for PPH
and corrective actions following PPH, as well as
emotions experienced when taking bolus
insulin, were found by diabetes type.
Conclusion: These findings shed light on how
patients with diabetes experience and manage
PPH on a day-to-day basis and have
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implications for improving diabetes
self-management. Clinicians and diabetes
educators should help patients address eating
habits and lifestyle issues that may contribute to
PPH.
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INTRODUCTION
Glycemic control is an important part of diabetes
self-management for patients with type 1 and
type 2 diabetes [1]. Research suggests that
adequate and timely glycemic control, as
measured by hemoglobin A1c (HbA1c) values,
reduces the risks of microvascular and
macrovascular complications related to diabetes
[1–4]. While research on diabetes management
has focused primarily on the role of HbA1c and
fasting plasma glucose (FPG) for the
measurement of glycemic control, recent data
suggest that blood glucose (BG) after eating or
post-prandial blood glucose (PPG), also plays an
important role in glycemic control and glycemic
variability on a day-to-day basis, and provide
additional information not captured by HbA1c
values [5]. In particular, elevated PPG or
post-prandial hyperglycemia (PPH) may be an
important consideration for improving glycemic
control and diabetes self-management, and
ultimately reduce the risk of diabetes-related
complications.
Currently, there is no consensus on the
definition of PPH in the research literature or
among clinical communities. The American
Diabetes Association (ADA), the International
Diabetes Federation (IDF), and the American
Association of Clinical Endocrinologists
(AACE), for instance, use different PPG targets
in their guidelines for clinicians and patients.
According to the ADA, the PPG target 1–2 h
post-meal is \180 mg/dL, while the IDF
recommends a PPG target of\160 mg/dL; the
AACE’s recommended PPG target 2 h post-meal
is\140 mg/dL [1, 2, 6]. A recent clinical study
based on the IDF threshold found that among
patients with type 2 diabetes not treated with
insulin therapy, 84% had experienced PPH at
least once in the previous week [7].
Post-prandial blood glucose (PPG) is an
important part of overall glycemic control, and
research has shown that PPH is associated with a
significantly increased risk of cardiovascular
disease (CVD) and cardiovascular events among
individuals with and those without diabetes
[8–10]. Some research suggests that PPG may be
a better predictor of cardiovascular events than
FPG [11, 12]. In addition to CVD and
cardiovascular events, several long-term studies
of individuals with and without diabetes have
shown that PPH or elevated post-challenge
glucose following an oral glucose tolerance test
is significantly associated with increased risks of
both all-cause mortality and CVD mortality
[11, 13–16], as well as pancreatic cancer
mortality [17]. PPH has also been associated with
a number of other negative health outcomes,
including decreased cognitive functioning
among elderly patients with type 2 diabetes [18],
oxidative stress, endothelial dysfunction,
retinopathy, and some cancers [2]. Research has
also suggested that PPHmay contribute to greater
use of healthcare resources and related costs
among diabetic patients [19]. Further, PPG
control may be particularly challenging for
diabetic patients who require more complex
insulin regimens, comprising, for example, a
combination of basal and bolus insulins. There is
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evidence thatpatientswith type1diabetes treated
with basal and bolus insulin face challenges in
calculating and adjusting their insulin doses over
time, and that theymay rely on bolus insulin as a
‘‘correction’’ following PPH, rather than
examining BG measurement patterns over time
and adjusting insulin doses accordingly to
improve overall BG control [20].
Despite the importance of PPH for diabetes
self-management, relatively little is knownabout
how patients with type 1 and type 2 diabetes
experience PPH in their daily lives and how PPH
contributes to the complexities of diabetes
self-management. We conducted a web-based
survey to better understand how patients with
type 1 and type 2 diabetes experience PPH and its
role in diabetes self-management.
METHODS
Aweb-based surveyofpatientswith type1or type
2 diabetes who self-administered bolus insulin
therapy was conducted in Germany, the United
Kingdom(UK), and theUnited States (USA), from
July toNovember 2013. The study received ethics
approval from the Copernicus Group
Institutional Review Board (Tracking #
TBG1-11-116) prior to commencement. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Informed consent was obtained from all patients
included in the study.
Survey Development
To develop the survey, semi-structured focus
groups were conducted with 77 participants
recruited by focus group facilities who were
diagnosed with diabetes and using bolus insulin
in Germany (n = 20), the UK (n = 17), and the
USA (n = 40). Survey items were generated
through the analysis of focus group
transcripts, based on adapted grounded theory
[21]. Once generated, survey items underwent
cognitive debriefing with 12 individuals
diagnosed with diabetes (recruited by focus
group facilities, but not participants in the
study focus groups) to reach consensus that
instructions and items were clear,
understandable, relevant and inoffensive, to
ensure the recall period was appropriate, and
to confirm that the format and structure of the
survey were acceptable. The final survey
comprised 85 questions and took
approximately 30 min to complete.
Participants
The web-based survey was administered to
participants recruited from research panels
maintained by professional market research
firms in the three countries via a secure
internet server, which participants accessed via
their computers. Potential respondents were
selected from pre-existing panels of individuals
who had previously agreed to be approached to
participate in surveys. These pre-existing panels
were used for research purposes only.
Respondents were required to complete a brief
online screening survey to ensure eligibility for
participation. During screening, panel
participants were not aware that a diagnosis of
diabetes was required for survey eligibility;
participants were also asked about a number of
other conditions they may have been diagnosed
with to reduce the risk of potential misreporting
of a diabetes diagnosis to participate in the
survey. Minimal incentives were provided for
panel participation.
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To be eligible for the survey, respondents
were required to meet the following criteria:
aged 18 years or older, diagnosed with type 1 or
type 2 diabetes by a physician or healthcare
professional, prescribed self-administered bolus
insulin therapy and not using pre-mixed insulin
or glucagon-like peptide-1 analogs. Use of oral
antidiabetic medication was permitted if
required. Based on the inclusion and exclusion
criteria, approximately 7% of panel participants
who were approached for the survey were
eligible to participate. Recruitment quotas
were established for each country for the
method of insulin administration (*20%
pump users and*80% injection), diabetes
type (*40% type 1 and*60% type 2), age
(*40%, 18–30 years; *40%, 31–60 years;
*20%, over 60 years), and work status (*50%
employed) to ensure adequate sampling across
groups and generalizability of results.
Respondents received a modest honorarium
(approximately $15 USD) for completing the
survey.
Survey Variables
All responses to the survey were self-reported.
The survey items assessed the following:
demographic and diabetes health status, PPG
management and experience of PPH, emotions
experienced when using bolus insulin, and
diabetes-related concerns.
Demographic variables included country,
age, gender, marital status, education level,
employment status, and number of hours
worked per week. Diabetes health status
characteristics included age at diagnosis,
diabetes type, age at onset of insulin therapy,
method of insulin administration, respondents’
perceptions of how well their diabetes was
controlled, and respondents’ perceptions of
their general health status. Dietary variables
were also assessed including the number of
skipped meals in the previous week and
whether the respondent ate at a restaurant, ate
takeout food, and/or had eaten at a friend’s
home in the past week. Physical activity was
also reported.
PPG/PPH and diabetes self-management
variables were respondent-reported based on
their experience of out-of-range BG after
eating in the past week (7 days). Measures
included the number of episodes of PPH and
episodes of post-prandial hypoglycemia in the
past week. Dichotomous variables indicating
experience of PPH and post-prandial
hypoglycemia in the past week were also
created. Respondents also reported on their
most recent episode of out-of-range PPG and
the number of days since this last incident.
Respondents whose most recent experience of
out-of-range PPG was PPH (as opposed to
post-prandial hypoglycemia or being unsure)
were asked additional questions about their
experiences of PPH, including how they knew
they were experiencing PPH, reasons for PPH,
situations and factors contributing to PPH,
and corrective actions taken following PPH.
Respondents were questioned on the
emotions they experienced when taking
bolus insulin doses (e.g., empowered,
grateful, worried, discouraged) and their level
of confidence in calculating bolus insulin
doses accurately. Respondents also reported
on general diabetes-related concerns,
indicating how worried they were about
using their prescribed insulin device,
hypoglycemic/hyperglycemic events, future
diabetes complications, whether insulin was
controlling their diabetes, whether they were
able to calculate bolus doses correctly, and
problems contacting their healthcare provider.
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Data Analysis
The sample size was chosen based on the
analysis plan and to ensure that comparisons
could be made across groups. Analyses of the
survey data included descriptive statistics
(means, standard deviations, percentages, and
ranges) and measures of association
(comparison of means and cross-tabulations).
Statistical significance tests were conducted
based on the type of analysis: ANOVA was
used for comparison of means among three
groups, and t tests were used for comparison of
means between two groups. Pearson’s Chi
square was used to test for significant
associations between categorical variables.
Experience of PPH was self-reported. The
number of episodes of PPH and episodes of
post-prandial hypoglycemia in the past week
were both trimmed at the top 5% level to
correct for potential over-reporting errors.
Respondent experiences of PPH, including
contributing factors and responses to PPH,
were based on questions asked of respondents
whose most recent out-of-range PPG episode
was PPH. Respondents with and without PPH in
the previous week were also compared in terms
of health and diabetes characteristics, emotions
when taking bolus insulin, diabetes-related
concerns, and diabetes self-management. All
analyses were conducted by country and by
diabetes type. IBM SPSS Statistics version 22




A total of 906 respondents in three countries
completed the survey [Germany, n = 305 (type
1, n = 130; type 2, n = 175); UK, n = 236 (type 1,
n = 117; type 2, n = 119), US, n = 365 (type 1,
n = 109; type 2, n = 256)]. In total, 39.3% of
respondents had type 1 diabetes, and 60.7% had
type 2 diabetes. Descriptive and health
characteristics by diabetes type are shown in
Table 1. The sample was predominantly white
and just over half male, and more than half of
participants reported being married/partnered
and employed. As expected, respondents with
type 1 diabetes were significantly younger, and
had a significantly younger age at diagnosis and
when they first started insulin therapy
compared with those with type 2 diabetes.
More than half of the respondents reported
that their diabetes was ‘‘well’’ or ‘‘very well’’
controlled (56.2%) and that their general health
status was ‘‘good,’’ ‘‘very good’’ or ‘‘excellent’’
(57.3%). Compared with respondents with type
2 diabetes, respondents with type 1 diabetes
were significantly more likely to report that
their diabetes was ‘‘well’’ or ‘‘very well’’
controlled (66.3% vs. 49.6%; p\0.001) and
that they were in ‘‘good,’’ ‘‘very good’’ or
‘‘excellent’’ health (69.1% vs. 49.6%;
p\0.001). Concerning diet and exercise
patterns, respondents had skipped an average
of 1.4 meals in the previous week, and over
three-quarters of respondents reported eating
out in the past week. Respondents with type 1
diabetes reported significantly more hours
undertaking moderate and hard physical
exercise in the past week compared with those
with type 2 diabetes (moderate: 4.0 vs. 3.1 h;
p\0.05; hard: 2.0 vs. 1.1 h; p\0.001).
Out-of-range Post-Prandial Glucose
in the Previous Week
Two-thirds of respondents (66.3%) indicated
experiencing some level of difficulty with
out-of-range PPG in the past week, with 7.0%
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reporting that it was ‘‘very’’ or ‘‘extremely’’
difficult, and 59.3% reporting that it was ‘‘a
little’’ or ‘‘somewhat’’ difficult to get their BG
stable after eating. Difficulty with out-of-range
PPG in the past week did not differ significantly
by diabetes type.
Table 1 Patient demographic and diabetes/health characteristics by diabetes type
Type 1 (n5 356) Type 2 (n 5 550) Total (n5 906)
Patient characteristics
Age (years), mean (SD)*** 37.4 (14.4) 47.4 (16.2) 43.5 (16.2)
Male, n (%) 196 (55.1) 316 (57.5) 512 (56.5)
White Caucasian, n (%) 320 (89.9) 495 (90.0) 815 (90.0)
Married or partnered, n (%) 197 (55.3) 337 (61.3) 534 (58.9)
College/grad school educated, n (%)* 159 (44.7) 200 (36.4) 359 (39.6)
Employed (yes), n (%)*** 231 (64.9) 288 (52.4) 519 (57.3)
Work hours per week, mean (SD)a 35.5 (13.1) 35.0 (10.6) 35.2 (11.7)
Diabetes/health characteristics
Age (years) at diagnosis, mean (SD)*** 20.2 (12.1) 35.6 (14.0) 29.6 (15.3)
Age (years) started insulin, mean (SD)*** 20.9 (12.4) 39.6 (16.0) 32.2 (17.3)
Insulin method, n (%)***
Syringe 111 (31.2) 187 (34.0) 298 (32.9)
Preﬁlled pen 173 (48.6) 314 (57.1) 487 (53.8)
Insulin pump 72 (20.2) 49 (8.9) 121 (13.4)
Diabetes well/very well controlled, n (%)*** 236 (66.3) 273 (49.6) 509 (56.2)
Health status good/very good/excellent, n (%)*** 246 (69.1) 273 (49.6) 519 (57.3)
Diet and exercise habits
Number of skipped meals past week, mean (SD) 1.3 (2.2) 1.4 (2.0) 1.4 (2.1)
Ate at restaurant in past week (yes), n (%) 175 (49.2) 302 (54.9) 477 (52.6)
Ate takeout in past week (yes), n (%) 125 (35.1) 205 (37.3) 330 (36.4)
Ate at friend’s home in past week (yes), n (%) 166 (46.6) 221 (40.2) 387 (42.7)
Any eating out in past week (yes), n (%) 267 (75.0) 427 (77.6) 694 (76.6)
Light physical activity past week, mean hours (SD) 7.5 (7.9) 6.9 (7.2) 7.2 (7.5)
Moderate physical activity past week, mean hours (SD)* 4.0 (6.4) 3.1 (4.3) 3.5 (5.2)
Hard physical activity past week, mean hours (SD)*** 2.0 (3.8) 1.1 (2.4) 1.5 (3.0)
Physical activity at work (yes), n (%)a 45 (19.5) 63 (21.9) 108 (20.8)
Chi-square/t tests indicate signiﬁcant differences by diabetes type, * p\0.05; *** p\0.001
a Restricted to employed respondents, n = 519
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As shown in Fig. 1, 61.9% of respondents
indicated that they experienced PPH in the past
week, 30.0% experiencing three or more
episodes in the past week. A total of 35.8% of
respondents experienced post-prandial
hypoglycemia in the past week, with 11.3%
experiencing three or more episodes in the past
week. Respondents reported an average of 1.7
episodes of PPH over the course of the week and
an average of 0.6 episodes of post-prandial
hypoglycemia during the last week.
Respondent Experiences and Management
of PPH
Respondents were asked to report on their most
recent episode of out-of-range PPG (Table 2);
52.3% indicated that their most recent
experience was PPH, while 28.4% indicated it
was post-prandial hypoglycemia, and 19.3%
were unsure. The average length of time since
this recent episode was 7.5 days. Respondents
whose last episode of out-of-range PPG was PPH
(n = 474) reported additional information on
this recent experience of PPH (Table 2). Most
respondents indicated that they knew they were
experiencing PPH because they tested their BG
(64.8%) and/or ‘‘just didn’t feel right’’ (51.9%).
Respondents who usually measured their BG
after meals with bolus insulin (n = 353)
reported testing their BG an average of
92.4 min after meals in the past week.
The most frequent (non-mutually exclusive)
reasons that respondents gave for PPH were: ate
more fat/sugar than estimated (31.2%), ate
more than they calculated their bolus insulin
dose for (30.4%), forgot to take their bolus
insulin dose (17.5%), calculated their bolus dose
incorrectly (16.7%) and/or took too little bolus













0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0
Experienced post-prandial hyperglycemia (PPH)
Experienced ≥ 3 episodes of PPH 
Experienced post-prandial hypoglycemia***
Experienced ≥ 3 episodes of post-prandial 
hypoglycemia** 
Percent of respondents 
Type 1 diabetes (n=356) Type 2 diabetes (n=550) Total (n=906)
Fig. 1 Out-of-range post-prandial blood glucose in the past week (7 days) by diabetes type. Responses were not mutually
exclusive. Chi-square tests indicate signiﬁcant differences by diabetes type, **p\0.01; ***p\0.001. PPH post-prandial
hyperglycemia
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(non-mutually exclusive) situations which
contributed to PPH were: stress (27.4%), eating
at a restaurant (24.9%), being busy (21.1%) and/
or feeling tired (19.2%).
The most frequently reported (non-mutually
exclusive) corrective actions taken by
respondents following PPH were: tested BG
and took bolus insulin based on the reading
Table 2 Respondents’ most recent experiences of post-prandial hyperglycemia by diabetes type
n (%)a Type 1 (n5 187) Type 2 (n5 287) Total (n5 474)
How respondent knew episode was PPH
Tested BG 116 (62.0) 191 (66.6) 307 (64.8)
Just didn’t feel right 100 (53.5) 146 (50.9) 246 (51.9)
Frequent urination 18 (9.6) 43 (15.0) 61 (12.9)
Other 9 (4.8) 21 (7.3) 30 (6.3)
Top 6 reasons given for PPH developing
Ate more fat/sugar than estimated 55 (29.4) 93 (32.4) 148 (31.2)
Ate more than calculated bolus dose for 56 (29.9) 88 (30.7) 144 (30.4)
Forgot to take bolus dose 30 (16.0) 53 (18.5) 83 (17.5)
Calculated bolus dose incorrectly 37 (19.8) 42 (14.6) 79 (16.7)
Took too little bolus insulin* 36 (19.3) 36 (12.5) 72 (15.2)
Because of stress 19 (10.2) 39 (13.6) 58 (12.2)
Top 5 situations/factors contributing to PPH
Stress** 36 (19.3) 94 (32.8) 130 (27.4)
Eating at a restaurant 43 (23.0) 75 (26.1) 118 (24.9)
Being busy 34 (18.2) 66 (23.0) 100 (21.1)
Feeling tired** 24 (12.8) 67 (23.3) 91 (19.2)
I do not know* 37 (19.8) 34 (11.8) 71 (15.0)
Corrective action taken following PPH
Tested BG and took bolus based on reading*** 134 (71.7) 160 (55.7) 294 (62.0)
Ate less/more carefully next meal/snack** 22 (11.8) 67 (23.3) 89 (18.8)
Waited, took bolus dose next time I ate 17 (9.1) 40 (13.9) 57 (12.0)
Took bolus dose without testing BG 17 (9.1) 39 (13.6) 56 (11.8)
Skipped next meal/snack 8 (4.3) 14 (4.9) 22 (4.6)
Other 6 (3.2) 15 (5.2) 21 (4.4)
Total took bolus dose** 147 (78.6) 191 (66.6) 338 (71.3)
Chi-square tests indicate signiﬁcant differences by diabetes type, * p\0.05; ** p\0.01; *** p\0.001
PPH post-prandial hyperglycemia, BG blood glucose
a Responses not mutually exclusive
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(62.0%) and/or ate less/more carefully for the
next meal or snack (18.8%). Of note, 12.0% of
respondents reported that they waited and took
a bolus dose with their next meal/snack, and
11.8% reported taking a bolus dose without
testing their BG.
Experiences of PPH differed somewhat by
diabetes type. Patients with type 1 diabetes,
when compared with those with type 2
diabetes, were significantly more likely to
indicate that they took too little bolus insulin
as a reason for PPH (19.3% vs. 12.5%; p\0.05).
Patients with type 2 diabetes were significantly
more likely to indicate both ‘‘stress’’ (32.8% vs.
19.3%, p\0.01) and ‘‘feeling tired’’ (23.3% vs.
12.8%; p\0.01) as contributing factors/
situations for PPH compared with patients
with type 1 diabetes. In terms of corrective
action following PPH, patients with type 1
diabetes were significantly more likely to
indicate that they tested BG and took a bolus
dose based on the reading (71.1% vs. 55.7% for
type 2 diabetes; p\0.001), whereas those with
type 2 diabetes were significantly more likely to
indicate that they ate less/more carefully at the
next meal/snack (23.3% vs. 11.8% for type 1
diabetes; p\0.01).
Comparison of Respondents Who Did
and Did Not Experience PPH
Respondents who did and did not experience
PPH in the past week were compared in terms of
diabetes and health characteristics, as well as
emotions when taking bolus insulin and
diabetes-related concerns. Regarding diabetes
characteristics, the method of insulin
administration differed significantly between
respondents who experienced PPH and those
who did not (p\0.001); while both groups were
approximately equally likely to use a syringe
(32.3% and 33.9%, respectively), respondents
who experienced PPH were less likely to use a
prefilled pen (48.8% vs. 61.7%) and somewhat
more likely to use an insulin pump (18.9% vs.
13.4%). Further, respondents who experienced
PPH were significantly less likely to report that
their diabetes was ‘‘well’’ or ‘‘very well’’
controlled (49.9% vs. 66.4%; p\0.001) or that
their general health status was ‘‘good,’’ ‘‘very
good’’ or ‘‘excellent’’ (54.4% vs. 62.0%; p\0.05)
compared with those who did not experience
PPH.
In terms of eating habits, respondents who
experienced PPH in the past week reported
skipping a significantly greater number of
meals in the past week (1.6 vs. 1.0; p\0.001)
and were significantly more likely to have eaten
out at a restaurant (57.2% vs. 45.2%; p\0.001),
eaten takeout food (40.1% vs. 30.4%; p\0.01),
and/or eaten at a friend’s home (46.3% vs.
36.8%; p\0.01) than those who did not
experience PPH. Reported physical activity did
not differ significantly between those who had
and had not experienced PPH in the past week.
Significant differences in emotions when
taking bolus insulin were evident, with those
who experienced PPH in the past week
significantly more likely to report feeling very/
extremely ‘‘grateful’’ (31.6% vs. 23.2%;
p\0.01), ‘‘worried’’ (10.2% vs. 5.2%; p\0.01),
‘‘guilty’’ (9.8% vs. 4.3%; p\0.01), ‘‘discouraged’’
(11.8% vs. 5.2%; p\0.01), ‘‘frustrated’’ (12.5%
vs. 6.4%; p\0.01), ‘‘embarrassed’’ (8.2% vs.
4.1%; p\0.05), and ‘‘angry’’ (9.3% vs. 4.6%,
p\0.05) when taking bolus insulin compared
with those who did not experience PPH
(Table 3). Additionally, those who experienced
PPH in the past week were significantly less
likely to report that they were very/extremely
confident in calculating their bolus doses
accurately (52.9% vs. 67.5%; p\0.001)
compared with those who did not experience
PPH. Regarding diabetes-related concerns, those
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who experienced PPH were significantly more
likely to indicate being very/extremely worried
about future diabetes complications (45.6% vs.
25.8%; p\0.001), whether insulin was
controlling their diabetes (30.1% vs. 13.0%;
p\0.001), high blood sugar events (30.7% vs.
9.6%; p\0.001), low blood sugar events (24.8%
vs. 11.3%; p\0.001), whether they were
calculating bolus insulin doses correctly
(21.6% vs. 10.7%; p\0.001), and using their
insulin devices (9.8% vs. 4.1%; p\0.01).
Associations between PPH and respondent
emotions when taking bolus insulin differed
somewhat by diabetes type. The positive
relationships between PPH and some emotions
when taking bolus doses were significant among
respondents with type 1 diabetes, but not
among those with type 2 diabetes, including
feeling very/extremely ‘‘grateful’’ (p\0.05) and
‘‘embarrassed’’ (p\0.05). In addition, the
associations between experience of PPH and a
number of emotions when taking bolus insulin
Table 3 Respondents’ feelings about bolus insulin and general worries related to diabetes according to whether they had
experienced post-prandial hyperglycemia in the past week (7 days)
n (%)a PPH in past
week (n5 561)




When you take your bolus insulin doses, do you feel very/extremely?
Grateful** 177 (31.6) 80 (23.2) 257 (28.4)
Empowered 122 (21.7) 66 (19.1) 188 (20.8)
Frustrated** 70 (12.5) 22 (6.4) 92 (10.2)
Discouraged** 66 (11.8) 18 (5.2) 84 (9.3)
Worried** 57 (10.2) 18 (5.2) 75 (8.3)
Guilty** 55 (9.8) 15 (4.3) 70 (7.7)
Angry* 52 (9.3) 16 (4.6) 68 (7.5)
Embarrassed* 46 (8.2) 14 (4.1) 60 (6.6)
Are you very/extremely conﬁdent that you really know how to
accurately calculate your bolus doses?***
297 (52.9) 233 (67.5) 530 (58.5)
In general, are you very/extremely worried about?
Future diabetes complications*** 256 (45.6) 89 (25.8) 345 (38.1)
If your insulin is controlling your diabetes*** 169 (30.1) 45 (13.0) 214 (23.6)
High blood sugar events*** 172 (30.7) 33 (9.6) 205 (22.6)
Low blood sugar events*** 139 (24.8) 39 (11.3) 178 (19.6)
If you are calculating insulin doses correctly*** 121 (21.6) 37 (10.7) 158 (17.4)
Problems contacting your healthcare provider 54 (9.6) 21 (6.1) 75 (8.3)
Using your insulin device** 55 (9.8) 14 (4.1) 69 (7.6)
Chi-square tests indicate signiﬁcant differences by experience of PPH in past week, * p\0.05; ** p\0.01; *** p\0.001
PPH post-prandial hyperglycemia
a Denotes proportion of patients answering yes
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were significant among respondents with type 2
diabetes, but not among those with type 1
diabetes, including feeling very/extremely
‘‘empowered’’ (p\0.05), ‘‘worried’’ (p\0.01),
‘‘frustrated’’ (p\0.01) or ‘‘angry’’ (p\0.05)
when taking bolus insulin, as well as
confidence in calculating their bolus insulin
dose (p\0.001). Additionally, the relationships
between PPH and some other diabetes-related
concerns were significant among respondents
with type 2 diabetes, but not among those with
type 1 diabetes, including being very/extremely
confident in calculating the bolus dose
(p\0.001) and being very/extremely worried
about hypoglycemic events (p\0.001), using
the insulin device (p\0.01), future diabetes
complications (p\0.001), and whether or not
they were calculating insulin doses correctly
(p\0.001).
DISCUSSION
Addressing PPH may be critical for achieving
better BG control, thereby reducing the risks of
diabetes-related complications and mortality
[8–17]. Consistent with prior research [2, 7],
this study shows that PPH occurs frequently
among patients with type 1 or type 2 diabetes.
This study adds to previous research by
examining how patients with diabetes
experience PPH in their everyday lives,
including causes and contributing factors to
PPH, as well as emotions surrounding bolus
insulin use and diabetes-related concerns
associated with PPH. Results indicate that
eating more than estimated and over-eating
with respect to the calculated bolus insulin dose
are frequently reported reasons for PPH, and
that a number of factors in one’s daily life,
including stress, eating out, being busy, and
feeling tired, may also contribute to PPH.
Experience of PPH was associated with more
negative emotions when taking bolus insulin
doses, less confidence in calculating bolus doses
accurately, and greater diabetes-related
concerns. Thus, the findings suggest that PPH
may be associated with an emotional burden
related to diabetes self-management. The
development of PPH also appears to be
associated with particular eating habits, for
example, eating out and skipped meals.
Overall, the findings illuminate how patients
with diabetes experience PPH in their
day-to-day lives and add to previous literature
indicating that the experience of hyperglycemia
has negative implications for quality of life and
well-being among patients with diabetes
[22, 23].
The findings from this web-based survey
have implications for both clinicians and
patients. Patient education and support
programs to help diabetic patients manage
their eating habits and lifestyle issues that may
contribute to PPH could help improve BG
control and reduce the number of episodes of
PPH. The provision of continuing education for
patients on the use of bolus insulin could also
help improve diabetes self-management and
increase patients’ confidence when calculating
their bolus insulin dose. Counseling and patient
support groups may also help mitigate negative
emotions surrounding bolus insulin use and
diabetes-related concerns associated with PPH.
The results also suggest some differences in
the experience of PPH according to diabetes
type. Patients with type 2 diabetes may be
particularly vulnerable to stress and tiredness as
contributing factors to PPH and are less likely to
measure their BG following PPH, compared
with type 1 diabetic patients. In terms of
emotions when using bolus insulin and
diabetes-related concerns associated with PPH,
it is difficult to draw general conclusions about
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differences according to diabetes type as the
results were somewhat mixed. Some
non-significant findings among respondents
with type 1 diabetes may be due to the smaller
sample size relative to respondents with type 2
diabetes. Additional research is needed to better
understand the influence of diabetes type on
emotions.
Finally, this study has some limitations
which should be considered. First, all survey
data were self-reported. As with any
self-reported survey, reporting accuracy may
be a concern, as recall bias may have impacted
the results. Unfortunately, data on actual BG
measurements were not available to confirm
respondents’ experiences of PPH or the severity
of episodes. Research, however, demonstrates
that the recall of non-severe hypoglycemic
episodes of up to 1 week may be considered
generally accurate [24]. Furthermore,
participants in the focus groups during the
survey development phase of the study
indicated that the recall periods used for the
survey were appropriate. Additionally,
physician-confirmed diagnosis of diabetes was
not possible, so some respondents may have
reported a diabetes diagnosis, diabetes type,
and/or treatment with bolus insulin therapy
inaccurately. It is unlikely, however, that such
respondents were large enough in numbers to
influence study results. Lastly, as with all studies
that use internet-based surveys, data may be
affected by selection bias related to respondent
participation, as only literate respondents with
computer and internet access could participate.
However, in the three countries studied, the
literacy rates and proportion of internet users
are both quite high. In the UK, for example, the
basic literacy rate of adults aged 15 years and
older is 99% [25], and approximately 83% of
households had internet access in 2013 [26].
CONCLUSION
In conclusion, these findings shed much
needed light on how patients with type 1
and type 2 diabetes experience PPH and how
PPH contributes to the complexities of
diabetes self-management. Clinicians and
diabetes educators should be aware of the
eating habits and lifestyle issues that may
contribute to PPH, including stress, being
busy, eating out, and skipped meals, so that
they can educate patients with diabetes on the
serious consequences of PPH and help them
develop targeted self-management strategies to
reduce PPH [2]. Clinicians should also be
mindful that experience of PPH may
contribute to negative emotions when using
bolus insulin, as well as greater
diabetes-related concerns. Additional patient
education and support programs may help
mitigate such negative emotions and
concerns. Future research should focus on
improving diabetes self-management and
treatments to reduce the incidence of PPH,
as well as explore broader and longer term
impacts of PPH. Further exploration of
country and cultural differences in the
experience of PPH would be of interest.
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